The FDA accepted the supplemental new drug applications (sNDA) and granted a priority review designation to finerenone (Kerendia; Bayer) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).1 The regulatory submission was based on positive results from the phase 3 FINEARTS-HF trial (NCT04435626),2 which were published in The New England Journal of Medicine.3
Finerenone is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that was initially approved by the FDA in July 2021 to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for HF in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes. In this population, the nsMRA has been recommended to improve cardiovascular outcomes and reduce the risk of CKD progression by the American Diabetes Association, as well as reduce cardiovascular and kidney failure risk in addition to standard of care by the European Society of Cardiology.1
Approximately 6.7 million US adults live with HF, a syndrome in which symptoms and signs can result from structural or functional impairment of the ventricular filling or ejection of blood. Approximately 55% of these patients have a LVEF of 40% or higher, and most also have multiple comorbidities, such as obesity, diabetes, hypertension, and CKD.1
“People with HFmrEF or HFpEF face substantial challenges in diagnosis, treatment, and follow-up care,” Robert Perkins, MD, MPH, FACP, vice president, US Medical Affairs, Bayer, in a news release. “In fact, a 2024 report on HF trends and outcomes published in the Journal of Cardiac Failure showed that in patients with HFpEF, 5-year mortality was 75.7%. The FDA’s decision to grant priority review designation to our application underlines the significant unmet need these patients face.”1